Listen to this story
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowThis audio file is brought to you by 
0:00
0:00
Loading audio file, please wait.
HemaQuest Pharmaceuticals, a startup in Newton, Mass., said today it has received $20 million in funding from Lilly Ventures, De Novo Ventures of Palo Alto, Calif.; and Forward Ventures of San Diego.
The amount of the investment by Lilly Ventures, the venture capital arm of Indianapolis-based Eli Lilly and Co., wasn’t specified.
HemaQuest is developing small molecule therapies to treat sickle cell anemia and other blood disorders.
Please enable JavaScript to view this content.